NASDAQ · CTKB

Cytek Biosciences, Inc.

$4.41 -$0.05 (-1.12%) 1D After hours

Key Metrics

$575.98M
Market cap
P/E · TTM
$204.17M
Revenue · TTM
−$74.00M
Net income
EPS · TTM $-0.58
Dividend yield
Free cash flow −$12.70M
Beta · 1Y 1.11
EBITDA · TTM −$29.47M
Gross margin 51.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 28
    Money has been moving out of its sector (Technology).

    Technology has run -4.1 points vs SPY over four weeks, ranking 8→2→11→7 of 11 sectors — this stock trades inside that current.

    RECEIPT: ROTATION MAP, LIVE ↗
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 14
    From its Feb 2 high, the share price fell 35%.

    Peak close $5.16 on Feb 2; trough close $3.36 on May 14. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -35%
  • May 13
    The stock moved -8.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 13
  • May 11
    The stock moved -10.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 11

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$575.98M
Enterprise value
Shares outstanding129.1M
52-wk range$3.28 – $6.18
Avg volume · 20D847.6K
Net cash
Book value / share$2.55
IndustryLaboratory Analytical Instruments
ExchangeNASDAQ
About Cytek Biosciences, Inc.
IPO dateJul 23, 2021
Employees702

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S2.82
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 51.7%
Operating -18.1%
Net -36.2%
FCF -6.2%
ROE / ROIC -20.5% · —

Financial Health

Current ratio4.69
Quick ratio4.07
Debt / equity
Debt / EBITDA
Net cash
Working capital$298.37M

Cash Flow · TTM

Operating CF −$7.30M
Capex −$5.40M
Free cash flow −$12.70M
Buybacks $4.45M
Dividends paid
Shareholder yield 0.8%

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

3.4
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings